Pylum Biosciences

Pylum Biosciences has developed and acquired the Avidocin™ platform technology, which is capable of producing bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be rapidly modified to generate new protein complexes to suppress emerging strains as soon as their genomic sequences become available.